Retrospective study of thalidomide plus dexamethasone versus conventional chemotherapy in the relapsed multiple myeloma patient and the study of melphalan and prednisone versus melphalan, prednisone, and thalidomide

Published: June 5, 2009
Abstract Views: 125
PDF: 140
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Thalidomide shows promise in the treatment of multiple myeloma (MM). Questions remain, however, about its efficacy compared with conventional chemo-therapy.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Boccadoro, M. (2009). Retrospective study of thalidomide plus dexamethasone versus conventional chemotherapy in the relapsed multiple myeloma patient and the study of melphalan and prednisone versus melphalan, prednisone, and thalidomide. Hematology Meeting Reports (formerly Haematologica Reports), 1(11). https://doi.org/10.4081/hmr.v1i11.351